Loading...
•
Jun 30
Erasca Q2 2025 Earnings Report
Erasca reported a reduced net loss in Q2 2025, supported by lower R&D and G&A expenses and a strong cash position.
Key Takeaways
Erasca posted a net loss of $33.9 million for Q2 2025, marking an improvement from the prior year. Operating expenses declined significantly, driven by lower R&D and G&A costs. The company ended the quarter with a strong balance sheet, supporting its ongoing clinical pipeline.
Net loss was $33,876,000 for Q2 2025, improved from $63,201,000 in Q2 2024
EPS was $(0.12) per share for the quarter
Cash, cash equivalents, and marketable securities totaled $386,749,000
R&D and G&A expenses declined compared to prior year, aiding reduced losses
Erasca
Erasca
Forward Guidance
Erasca plans to advance ERAS-0015 and ERAS-4001 through Phase 1 trials, with sufficient cash runway into the second half of 2028.
Positive Outlook
- Cash runway expected to fund operations into H2 2028
- INDs cleared for ERAS-0015 and ERAS-4001
- Clinical trials for pan-RAS and pan-KRAS inhibitors underway
- Reduced R&D and G&A costs aid financial stability
- Encouraging preclinical data supports pipeline progression
Challenges Ahead
- No revenue reported; company still pre-commercial
- Continued net losses despite cost reductions
- Dependence on clinical trial outcomes for key candidates
- Potential delays in data readouts and trial progression
- Ongoing need for strategic collaborations and licensing